Icotrokinra
Icotrokinra, sold under the brand name Icotyde, is a medication used for the treatment of plaque psoriasis.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Icotrokinra, sold under the brand name Icotyde, is a medication used for the treatment of plaque psoriasis. It is a cyclic peptide that functions as a selective interleukin 23 (IL-23) receptor antagonist. It is a synthetic peptide that binds selectively to the IL-23 receptor (IL-23R) with high affinity and competitively antagonizes the binding of IL-23.
It is an immunosuppressant and interleukin inhibitor. It is being developed by Johnson & Johnson. Icotrokinra was approved for medical use in the United States in March 2026.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1378710068 under CC BY-SA 4.0; modifications have been made.